Stratasys (SSYS) Q3 2024 earnings summary

Executive summary

• Achieved a return to adjusted profitability in Q3 2024 through decisive cost-cutting, operational streamlining, and restructuring, positioning for growth and improved margins in manufacturing, especially automotive, defense, aerospace, medical devices, and dental.

• Launched new products including the F3300 industrial platform, Origin Two, Origin Cure, and Neo Build Processor, targeting high-growth manufacturing and dental sectors.

• Eighth consecutive quarter of year-over-year growth in recurring consumables revenue, highlighting stability and strong printer utilization.

• Strategic focus on megatrends such as supply chain resilience, onshoring, customization, sustainability, and digitalization to support long-term demand.

• Board approved a $50 million share repurchase plan, already underway to enhance shareholder value.

Financial highlights

• Q3 2024 consolidated revenue was $140 million, down 13.6% year-over-year due to softness in capital equipment spending.

• Product revenue was $94.1 million (down 16.9% year-over-year); system revenue $31.7 million (down 38.4%); consumables revenue grew 1% to $62.4 million.

• Service revenue was $45.9 million (down 6.1% year-over-year); customer support revenue up 1.3%.

• GAAP gross margin improved to 44.8% (up 430bps); non-GAAP gross margin rose to 49.6%, the highest since Q4 2019.

• GAAP net loss narrowed to $26.6 million ($0.37/share) from $47.3 million ($0.68/share) last year; non-GAAP net income was $0.4 million ($0.01/share).

• Adjusted EBITDA was $5.1 million, down from $9.8 million last year.

• Cash used in operations was $4.5 million (vs. $12.7 million last year); quarter-end cash and equivalents $144 million.

Outlook and guidance

• Full-year 2024 revenue expected between $570 million–$580 million.

• Gross margin guidance raised to 49%–49.2% for 2024; non-GAAP operating margin expected at 0.6%–1.3%.

• GAAP net loss forecasted at $105 million–$90 million ($1.48–$1.27/share); non-GAAP net income $2.1 million–$5 million ($0.03–$0.07/share).

• Adjusted EBITDA expected at $25–$28 million; capital expenditures $15–$20 million.

• 2025 EBITDA margin expected at 8% with flat revenue, potentially 10%+ with moderate growth.